OBJECTIVE: The central nervous system can regulate peripheral inflammation, but the efferent neuronal routes and the mediators remain poorly defined. One candidate is the cholinergic pathway, which releases acetylcholine (ACh). This neurotransmitter can bind to the alpha7 cholinergic receptor (alpha7R) expressed by nonneuronal cells and reduce inflammation. To test this possibility, we evaluated the expression of alpha7R and its potential role as a target in rheumatoid arthritis (RA). METHODS: The expression of alpha7R in human synovium and fibroblast-like synoviocytes (FLS) was determined using immunohistochemical, Western blot, and quantitative polymerase chain reaction (PCR) analyses. The effects of ACh in vitro were determined in interleukin-1 (IL-1)-stimulated FLS using immunoassays for protein, quantitative PCR for messenger RNA (mRNA), luciferase reporter constructs for IL-6 and NF-kappaB promoter activity, and electrophoretic mobility shift assays. Expression of alpha7R was knocked down with small interfering RNA (siRNA) or was inhibited with the selective alpha7R antagonist methyllycaconitine (MLA). RESULTS: Protein and mRNA for alpha7R were demonstrated in RA and osteoarthritis synovium and cultured synoviocytes. Expression in synovium was mainly in the intimal lining. ACh significantly reduced the production of IL-6, CXCL8, CCL2, CCL3, CCL5, and granulocyte colony-stimulating factor by IL-1-stimulated FLS. This effect was blocked by the alpha7R antagonist MLA or by using alpha7R siRNA to knock down receptor expression. The selective alpha7R agonist PNU-282,987 decreased the production of IL-6 by IL-1-stimulated FLS. ACh did not reduce IL-6 transcription, but it decreased IL-6 mRNA half-life and reduced IL-6 mRNA steady-state levels. CONCLUSION: The alpha7 receptor is expressed in the synovium and by synoviocytes. Receptor ligation inhibits cytokine expression in FLS through a posttranscriptional mechanism. Therefore, alpha7R is a potential therapeutic target for inflammatory diseases.
OBJECTIVE: The central nervous system can regulate peripheral inflammation, but the efferent neuronal routes and the mediators remain poorly defined. One candidate is the cholinergic pathway, which releases acetylcholine (ACh). This neurotransmitter can bind to the alpha7 cholinergic receptor (alpha7R) expressed by nonneuronal cells and reduce inflammation. To test this possibility, we evaluated the expression of alpha7R and its potential role as a target in rheumatoid arthritis (RA). METHODS: The expression of alpha7R in human synovium and fibroblast-like synoviocytes (FLS) was determined using immunohistochemical, Western blot, and quantitative polymerase chain reaction (PCR) analyses. The effects of ACh in vitro were determined in interleukin-1 (IL-1)-stimulated FLS using immunoassays for protein, quantitative PCR for messenger RNA (mRNA), luciferase reporter constructs for IL-6 and NF-kappaB promoter activity, and electrophoretic mobility shift assays. Expression of alpha7R was knocked down with small interfering RNA (siRNA) or was inhibited with the selective alpha7R antagonist methyllycaconitine (MLA). RESULTS: Protein and mRNA for alpha7R were demonstrated in RA and osteoarthritis synovium and cultured synoviocytes. Expression in synovium was mainly in the intimal lining. ACh significantly reduced the production of IL-6, CXCL8, CCL2, CCL3, CCL5, and granulocyte colony-stimulating factor by IL-1-stimulated FLS. This effect was blocked by the alpha7R antagonist MLA or by using alpha7R siRNA to knock down receptor expression. The selective alpha7R agonist PNU-282,987 decreased the production of IL-6 by IL-1-stimulated FLS. ACh did not reduce IL-6 transcription, but it decreased IL-6 mRNA half-life and reduced IL-6 mRNA steady-state levels. CONCLUSION: The alpha7 receptor is expressed in the synovium and by synoviocytes. Receptor ligation inhibits cytokine expression in FLS through a posttranscriptional mechanism. Therefore, alpha7R is a potential therapeutic target for inflammatory diseases.
Authors: Wouter J de Jonge; Esmerij P van der Zanden; Frans O The; Maarten F Bijlsma; David J van Westerloo; Roelof J Bennink; Hans-Rudolf Berthoud; Satoshi Uematsu; Shizuo Akira; Rene M van den Wijngaard; Guy E Boeckxstaens Journal: Nat Immunol Date: 2005-07-17 Impact factor: 25.606
Authors: Alice L Bodnar; Luz A Cortes-Burgos; Karen K Cook; Dac M Dinh; Vincent E Groppi; Mihaly Hajos; Nicole R Higdon; William E Hoffmann; Raymond S Hurst; Jason K Myers; Bruce N Rogers; Theron M Wall; Mark L Wolfe; Erik Wong Journal: J Med Chem Date: 2005-02-24 Impact factor: 7.446
Authors: David L Boyle; Toni L Jones; Deepa Hammaker; Camille I Svensson; Sanna Rosengren; Salvatore Albani; Linda Sorkin; Gary S Firestein Journal: PLoS Med Date: 2006-09 Impact factor: 11.069
Authors: David L Boyle; Sanna Rosengren; William Bugbee; Arthur Kavanaugh; Gary S Firestein Journal: Arthritis Res Ther Date: 2003-10-08 Impact factor: 5.156
Authors: R B Gonçalves; R D Coletta; K G Silvério; L Benevides; M Z Casati; J S da Silva; F H Nociti Journal: Inflamm Res Date: 2011-02-05 Impact factor: 4.575
Authors: Lisa C Loram; Jacqueline A Harrison; Lindsey Chao; Frederick R Taylor; Anireddy Reddy; Carissa L Travis; Rona Giffard; Yousef Al-Abed; Kevin Tracey; Steven F Maier; Linda R Watkins Journal: Brain Behav Immun Date: 2010-03-28 Impact factor: 7.217
Authors: Dana E Orange; Phaedra Agius; Edward F DiCarlo; Nicolas Robine; Heather Geiger; Jackie Szymonifka; Michael McNamara; Ryan Cummings; Kathleen M Andersen; Serene Mirza; Mark Figgie; Lionel B Ivashkiv; Alessandra B Pernis; Caroline S Jiang; Mayu O Frank; Robert B Darnell; Nithya Lingampali; William H Robinson; Ellen Gravallese; Vivian P Bykerk; Susan M Goodman; Laura T Donlin Journal: Arthritis Rheumatol Date: 2018-04-02 Impact factor: 10.995
Authors: S J Kolker; R Y Walder; Y Usachev; J Hillman; D L Boyle; G S Firestein; K A Sluka Journal: Ann Rheum Dis Date: 2009-11-23 Impact factor: 19.103
Authors: Sofia S Lindblad; Piotr Mydel; Ing-Marie Jonsson; Robert M Senior; Andrej Tarkowski; Maria Bokarewa Journal: Arthritis Res Ther Date: 2009-06-11 Impact factor: 5.156